Juswinder Singh

This inventor holds 68 USPTO granted patents and 14 published patent applications, plus 8 CIPO patents and 7 EPO patents, primarily in Protein Kinase Inhibitors (CPC class C07D). Top assignees: Celgene Avilomics Research, Inc., Celgene Car LLC, Sanofi. Active years: 2002-2023.

USPTO Granted Patents = 68 (Patent Applications = 14)

% Patents Active = 67.6

CIPO Patents = 8 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 19)

Average Co-Inventor Count = 6.2

ph-index = 15

Forward Citations = 1,005(Granted Patents)

Forward Citations (Not Self Cited) = 611(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Malden, MA (US) (2002 - 2003)
Ashland, MA (US) (2003 - 2023)
Southborough, MA (US) (2015 - 2023)

Company Filing History:

31 out of 44

Celgene Avilomics Research, Inc.

Avila Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2002-2023

Loading Chart...

Areas of Expertise:

MK2 Inhibitors

ERK Inhibitors

HCV Protease Inhibitors

Protein Kinase Conjugates

Heterocyclic Compounds

2,4-Disubstituted Pyrimidines

Substituted Pyrido[2,3-D]Pyrimidines

Ligand-Directed Modification

Kinase Inhibitors

Substituted 2,4-Diaminopyrimidines

Heteroaryl Compounds

68 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11584757 - MK2 inhibitors and uses thereof (2023-02-21),

2. 11542492 - Ligand-directed covalent modification of protein (2023-01-03),

3. 11351168 - 2,4-disubstituted pyrimidines useful as kinase inhibitors (2022-06-07),

4. 11098061 - MK2 inhibitors and uses thereof (2021-08-24),

5. 11096942 - Heterocyclic compounds and uses thereof (2021-08-24),

6. 10828300 - Substituted 2,4-diaminopyrimidines as kinase inhibitors (2020-11-10),

7. 10774052 - Heteroaryl compounds and uses thereof (2020-09-15),

8. 10662195 - Protein kinase conjugates and inhibitors (2020-05-26),

9. 10618902 - Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases (2020-04-14),

10. 10596172 - 2,4-disubstituted pyrimidines useful as kinase inhibitors (2020-03-24),

11. 10577380 - MK2 inhibitors and uses thereof (2020-03-03),

12. 10434101 - Heterocyclic compounds and uses thereof (2019-10-08),

13. 10253040 - MK2 inhibitors and uses thereof (2019-04-09),

14. 10189794 - Heteroaryl compounds and uses thereof (2019-01-29),

15. 10138256 - MK2 inhibitors and uses thereof (2018-11-27),

Title: Innovator Spotlight: Juswinder Singh

Introduction

Juswinder Singh is a prominent inventor located in Ashland, MA, USA, known for his substantial contributions to the field of pharmaceuticals. With a remarkable portfolio of 68 patents, his innovative work focuses on enzyme inhibitors and their applications, significantly impacting drug development.

Latest Patents

Singh's latest patents include groundbreaking inventions such as "MK2 inhibitors and uses thereof," which presents compounds and compositions, along with methodologies for their utilization. Another notable patent is centered around "Ligand-directed covalent modification of protein," which involves enzyme inhibitors and details a method of designing such modifications, coupled with pharmaceutical formulations and applications in therapeutics.

Career Highlights

Throughout his career, Juswinder Singh has collaborated with renowned companies, notably Celgene Avilomics Research, Inc. and Celgene Car LLC. His work has been pivotal in advancing understanding and treatment options within the pharmaceutical industry.

Collaborations

Singh has worked alongside esteemed colleagues such as Russell Colyn Petter and Deqiang Niu, enhancing the synergy of innovation and research in his field. These collaborations have played a crucial role in the successful development of many of his patented inventions.

Conclusion

Juswinder Singh stands out as a remarkable inventor whose contributions to producing novel pharmaceuticals continue to push the boundaries of medical science. His extensive patent portfolio and collaborations underline his commitment to improving therapeutic strategies and patient care.